Endo Sweats On Vasostrict Competition While Varenicline Is A Boon
Sterile Injectable Unit Impaired By Hundreds Of Millions Of Dollars
Executive Summary
Endo management turned talk once again to its expectations for Vasostrict competition in the coming months during its year-end earnings call. The US-based firm enjoyed a better end to the year as it capitalized on the opportunity for shortage-hit varenicline.
You may also be interested in...
Eagle Aims To Meet Extra Vasopressin Demand Caused By Covid
Eagle management provided detailed insight into the existing market for vasopressin, which it entered in January with the first generic version of Endo’s Vasostrict. The US-based player believes operating cash flows for the year, boosted also by its Pemfexy (pemetrexed) launch, could top $170m, paving the way for a major acquisition.
Dr Reddy’s, American Regent And Endo Add Vasopressin Alternatives
Hot on the heels of Eagle’s first US generic launch, Dr Reddy’s has launched an authorized generic version of vasopressin at the same time as Endo’s Par Sterile Products has also launched a new pre-mixed ready-to-use presentation of the Vasostrict brand. Meanwhile, American Regent has also launched its 505(b)(2) product referencing Vasostrict.
Eagle Bags Vasopressin Exclusivity And Details Launch Plans
Generic competition to Vasostrict is nearing in the US after the FDA confirmed Eagle’s previously unresolved potential for 180-day market exclusivity.